NCT03097588View on ClinicalTrials.gov

Netupitant and Palonosetron Hydrochloride in Preventing Chemotherapy Induced Nausea and Vomiting in Patients With Cancer Undergoing BEAM Conditioning Regimen Before Stem Cell Transplant

PHASE2CompletedINTERVENTIONAL
Enrollment

43

Participants

Timeline

Start Date

April 27, 2017

Primary Completion Date

February 20, 2020

Study Completion Date

March 20, 2020

Conditions
Malignant Neoplasm
Interventions
DRUG

Netupitant

300 mg, Given PO, QD

DRUG

Palonosetron Hydrochloride

0.5 mg, Given PO, QD

OTHER

Questionnaire Administration

Ancillary studies

Trial Locations (1)

97239

OHSU Knight Cancer Institute, Portland

All Listed Sponsors
collaborator

Helsinn Therapeutics (U.S.), Inc

INDUSTRY

collaborator

Oregon Health and Science University

OTHER

lead

OHSU Knight Cancer Institute

OTHER

NCT03097588 - Netupitant and Palonosetron Hydrochloride in Preventing Chemotherapy Induced Nausea and Vomiting in Patients With Cancer Undergoing BEAM Conditioning Regimen Before Stem Cell Transplant | Biotech Hunter | Biotech Hunter